In this context, AFM28-mediated ADCC activity was also evident against AML cell lines and leukemic blasts with very low CD123 target antigen expression levels (below 200 antigens per cell as approximated by CD123-specific antibody binding capacity (SABC)). This evidence concerns the gene IL3RA and acute myeloid leukemia.